Update on treatments for diabetic macular edema
Authors:
- Samantha Fraser-BellSFSamantha Fraser-Bell
- Andrew KainesAKAndrew Kaines
- Phillip G HykinPHPhillip G Hykin
- 1 May 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 19 (3) , 185-189
Abstract
Due to modest outcomes with macular laser, other treatment modalities for diabetic macular edema have been evaluated. Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral protein kinase C inhibitors and, from more recently, anti-vascular endothelial growth factor therapy are reviewed. Intravitreal triamcinolone acetonide may be more effective than laser. Intravitreal triamcinolone acetonide followed by laser may be more effective than intravitreal triamcinolone acetonide alone. Ruboxistaurin, a selective protein kinase C betainhibitor, reduced retinal vascular leakage in patients with diabetic macular edema and reduced the rate of sustained moderate visual loss in those with moderately severe to very severe non proliferative diabetic retinopathy. Several anti-vascular endothelial growth factor agents are under evaluation. Intravitreal pegaptanib sodium (0.3 mg) improved vision and reduced central retinal thickness compared to sham. Data on the other anti-vascular endothelial growth factor agents is limited, but there are promising results, with ranibizumab (0.5 mg) and bevacizumab reducing foveal thickness and improving visual acuity in some patients with diabetic macular edema. There remains no proven intervention that consistently prevents or reverses visual loss from diabetic macular edema in all patients. A variety of promising new medical and surgical therapies are under investigation, but further research is required to determine their role alone or in combination.Keywords
This publication has 42 references indexed in Scilit:
- A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular EdemaOphthalmology, 2007
- Results of Visual Acuity and Foveal Thickness in Diabetic Macular Edema after VitrectomyJapanese Journal of Ophthalmology, 2007
- LONG-TERM OUTCOMES OF PARS PLANA VITRECTOMY WITH INTERNAL LIMITING MEMBRANE REMOVAL IN DIABETIC MACULAR EDEMARetina, 2007
- Comparison of the Modified Early Treatment Diabetic Retinopathy Study and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular EdemaArchives of Ophthalmology (1950), 2007
- A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedemaBritish Journal of Ophthalmology, 2007
- Effect of Ruboxistaurin on Visual Loss in Patients with Diabetic RetinopathyOphthalmology, 2006
- Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlationsEye, 2005
- A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular EdemaOphthalmology, 2005
- Effect of Ruboxistaurin on Blood–Retinal Barrier Permeability in Relation to Severity of Leakage in Diabetic Macular EdemaInvestigative Ophthalmology & Visual Science, 2005
- Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulationEye, 2005